NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Aquestive an ...

AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & KorsinskyMar 24, 2026 4:00 PM Eastern Daylight TimeAQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & KorsinskyShareImportant Information Regarding Section 20(a) ...

Robbins LLP Urges AQST Stockholders Who Lost Money Investing in Aquestive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action Accessibility StatementSkip Navigation SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLPreminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - March 23, 202 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Aquestive and its executives failed to disclose significant deficiencies in the NDA for Anaphylm, particularly regarding human factors in the use of its sublingual film [5]. Group 2: Stock Price Impact - Following the announcement of deficiencies in the NDA by the FDA on January 9, 2026, Aquestive's stock price dropped by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share [6]. Group 3: Firm Background and Outreach - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Aquestive's conduct [8].

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=184646&from=3 CL ...

Core Viewpoint - Aquestive Therapeutics, Inc. has appointed Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, succeeding Lori J. Braender, who will remain as Corporate Secretary [1][5] Company Leadership Changes - Thomas A. Zalewski brings extensive experience in life sciences law and has previously served as a Partner and Chair of the Healthcare and Life Sciences practice at Day Pitney LLP [1][2] - Lori J. Braender has served as Chief Legal Officer and Chief Compliance Officer since September 2018 and will continue as Corporate Secretary after her transition [3][5] Compensation and Inducement - Mr. Zalewski will receive an equity award of 100,000 Restricted Stock Units and 75,000 non-qualified common stock options as part of his inducement to join the company [4] - The equity awards will vest over three years, with 25% vesting after the first and second anniversaries, and 50% on the third anniversary [4] Company Overview - Aquestive Therapeutics is focused on advancing medicines through innovative science and delivery technologies, operating as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [6] - The company is known for its PharmFilm® technology and is advancing Anaphylm™, the first oral epinephrine rescue medication, towards FDA approval [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by May 4, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, particularly downplaying the significance of human factors in the use of its sublingual film [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages [5].

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the “Class Period”), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...